Lv0
0 积分 2023-01-03 加入
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
1天前
已完结
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies
2天前
已完结
Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond
2天前
已完结
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
2天前
已完结
Improvement ofYersinia frederikseniiphytase performance by a single amino acid substitution
3天前
已完结
231 Molecular insights on safety and anti-tumor activity of a non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392
17天前
已完结
Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement
17天前
已完结
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
17天前
已完结
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies
19天前
已完结
Abstract 5215: MOA study of KD050, an anti-PD-1/IL-15 bi-functional antibody selectively targeted PD-1 positive tumor-infiltrating lymphocytes resulted in robust anti-tumor activity and low systemic toxicity
1个月前
已关闭
皖公网安备34019202002308
